Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036634 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
A Phase 1 study of HIV Infections, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT00036634 is a Phase 1 study of HIV Infections that has completed, run by Gilead Sciences. The registered enrollment target is 30 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00036634, a Phase 1 study of HIV Infections, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
Conditions Studied
Interventions
- DRUG Tenofovir alafenamide
- DRUG Tenofovir DF
Study Locations (3)
California
- Stanford Positive Care Program - Palo Alto
Illinois
- Protocare Trials Chicago Center for Clinical Trials - Chicago
New York
- Rockefeller University Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-03 |
| Est. Completion | 2003-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036634
The ClinicalTrials.gov registry entry for NCT00036634 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Tenofovir alafenamide is the first listed.
NCT00036634 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00036634 about?
NCT00036634 is a clinical study titled "A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients". This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
What is the current status of trial NCT00036634?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2002-03. Estimated completion is 2003-02.
What conditions does trial NCT00036634 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00036634?
The interventions under investigation include: Tenofovir alafenamide (DRUG), Tenofovir DF (DRUG).
Who is sponsoring clinical trial NCT00036634?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00036634 being conducted?
This trial has 3 study locations across California, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.